The Medical Letter on Drugs and Therapeutics
November 5, 2007
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
A Once-Yearly IV Bisphosphonate for Osteoporosis
November 5, 2007 (Issue: 1273)Zoledronic acid (Reclast - Novartis) is the first bisphosphonate approved by the FDA for once-yearly intravenous (IV) treatment of osteoporosis in postmenopausal women. Reclast is also approved for treatment of Paget's disease. Another IV formulation...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.